



Roles of p53 Family in Cancers and Their Therapeutic Approaches

Guest Editors:

Dr. Bi-He Cai

School of Medicine, I-Shou
University, Kaohsiung City 82445,
Taiwan

Dr. I-Lun Hsin

Institute of Medicine, Chung Shan
Medical University, Taichung City
40201, Taiwan

Deadline for manuscript
submissions:

31 October 2024

Message from the Guest Editors

Throughout history, Chinese philosophers have used the concept “Yin” and “Yang” to describe inseparable opposites. The Yin represents dark or negative imagery, while the Yang represents light or positive imagery. The p53 family has the following three members: p53, p63 and p73. In cancer cells, the wild types of p53 or TA isoforms of p63 and p73 are described as the “Yin” and are used to block cancer progression. Most of the mutations of p53 or shorten isoforms of p53 family members ($\Delta 133p53$ and $\Delta 160p53$, $\Delta Np63$ and $\Delta Np73$) are described as the “Yang” and are used to promote cancer progression. The identification of the ways in which we can target mutant p53 or activate either p63 or p73 is purpose of cancer therapy. The Special Issue seeks to collect manuscripts (original research or reviews) on all p53 family members to study the “Yin” or “Yang” roles of p53 or p63 or p73 in cancers.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)